LEARNING OBJECTIVES
Upon completion of the activity, participants should be able to:

• Review MS diagnostic criteria, reasons for misdiagnosis, and red flags for misdiagnosis
• Recognize the significance of MS phenotypes, characteristic features, with an emphasis on progressive disease

FACULTY
Fred D. Lublin, MD
Professor of Neurology
Director of the Corinne Dickinson Center for MS
Mount Sinai Medical Center

Robert K. Shin, MD
Professor, Department of Neurology
Director, Georgetown Multiple Sclerosis and Neuroimmunolgy Center
Georgetown University Medical Center

ACCREDITATION AND CREDIT INFORMATION
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

TARGET AUDIENCE
This activity was developed for neurologists, nursing professionals, and other members of the health care team who care for patients with MS.

STATEMENT OF NEED
In light of the recent, rapid pace of pharmacotherapy development and availability in MS, it becomes especially crucial that neurologists and other health care providers are well equipped to evaluate and apply data on the latest therapies to the complex task of initial and subsequent treatment selection. While the focus of the current clinical and research climate is often on newer therapies with innovative mechanisms, it remains important that neurologists and others remain up-to-date on data and options pertaining to established therapies as well. It is equally essential that clinicians are equipped with evidence-based knowledge and skills that facilitate timely and accurate evaluations of disease activity and progression, both clinically and radiologically, as a means of informing prognosis and optimal treatment selection. Finally, despite the proven benefit of comprehensive, coordinated care to patients, many clinicians still function in clinical “silos” instead of working seamlessly together to prevent a fragmented health care experience with little care coordination for the patient. All of these gaps present opportunities for ongoing education.

CREDIT DESIGNATION
Physicians: The CMSC designates this activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The CMSC designates this enduring material for 0.25 contact hours of continuing education (none in the area of pharmacology).

Certificate of Completion: A Certificate of Completion may be given upon completion of course requirements enabling you to register your credit with the appropriate licensing boards or associations. You may apply for other accreditations using the procedure established by the specific organization.

OFF LABEL STATEMENT
The Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation (TFF) require CME/CE faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. CMSC and TFF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, the Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation (TFF) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. CMSC and TFF resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and TFF seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and TFF are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, continuing education committee, or other members at CMSC who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Activity Faculty
The following faculty report that they have relevant financial relationships to disclose:

• Fred D. Lublin, MD, has served as a speaker for Sanofi. He has done research for Actelion, Biogen, Brainstorm Cell Therapeutics, The National Institute of Health, The National Multiple Sclerosis Society, Novartis Pharmaceuticals, and Sanofi. He has also consulted and served on advisory boards for Acorda, Actelion/Janssen, Apitope, Atara, Avotres, Biotherapeutics, Biogen Idec, Brainstorm Cell Therapeutics, EMD Serono, GW Pharma, Immunic, Innate Immunotherapeutics, Jazz Pharmaceuticals, Mapi Pharma, Medday, MedImmune/Viela Bio, Mylan, Novartis, Orion Biotechnology, Polpharma, Population Council, Receptos/Celgene, Genentech/Roche, Sanofi/Genzyme, Teva, and TG Therapeutics.
• Robert K. Shin, MD, has served as a consultant for Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mallinckrodt, Novartis, Sanofi Genzyme, and VielaBio; on speakers bureaus for Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Mallinckrodt, Novartis, Sanofi Genzyme, and VielaBio; and as a contract researcher for Genentech.

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an educational grant from Biogen and Sanofi Genzyme.

DISCLAIMER
Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation (TFF) present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, Consortium of Multiple Sclerosis Centers, and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2021 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except when such information is required for reporting purposes to the ACCME, ANCC, and/or ACPE.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at www.francefoundation.com/privacy-policy.

CONTACT INFORMATION
If you have questions about this activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.